|Articles|September 1, 1996

September 1996
Volume 2
Issue 8

Pharmacoeconomic Evaluation of HMG-CoA Reductase Inhibitors in the Treatment of Hypercholestrolemia

Author(s)Sheldon Xiaodong Kong, PhD, Sanjay K. Gandhi, MS, Stephanie Y. Crawford, PhD

Download PDF: Pharmacoeconomic Evaluation of HMG-CoA Reductase Inhibitors in the Treatment of Hypercholestrolemia

Articles in this issue

over 29 years ago

Article

Determinants of Hospital Charges and Costs in Acute Myocardial Infarction: A Report from the Myocardial Infarction Cost Study (MICS) Group

over 29 years ago

Article

The Effectiveness of Postgraduate Education on the Clinical Breast Examination Skills of Primary Care Physicians

over 29 years ago

Article

Treatment Outcome in an Outpatient Asthma Center: Retrospective Questionnaire Data

over 29 years ago

Article

Potential Cost-Effectiveness of Acute Stroke Treatment

over 29 years ago

Article

Effect of a Comprehensive Nurse-Managed Diabetes Program: An HMO Prospective Study

over 29 years ago

Article

The Economic Organization of Health Resource Allocation: Decision Making in the New Environment

over 29 years ago

Article

Potential for SSRIs as Monotherapy for Comorbid Psychiatric Disorders

over 29 years ago

Article

Establishing the Basis for Successful Disease Management Contracting

over 29 years ago

Article

Accreditation Standards in Managed Care

over 29 years ago

Article

A Closer Look at Capitation

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Pharmacoeconomic Evaluation of HMG-CoA Reductase Inhibitors in the Treatment of Hypercholestrolemia

Articles in this issue

Newsletter

Related Content

Quality of Life: The Pending Outcome in Idiopathic Pulmonary Fibrosis

Increased Payments to Medicare Advantage Plans for Dually Eligible Beneficiaries

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

Building Trust: Public Priorities for Health Care AI Labeling

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

5 Things to Know About the Oral GLP-1 Era

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD